MYC and mantle cell lymphoma: Bromo-domain extra-terminal (BET) proteins targeting PROTAC (ARV-825 and ARV771; Arvinas, Inc., New Haven, CT, USA) have shown significant efficacy both in in-vitro and in-vivo xenograft models of Myc-dependent malignancies such as ABC-like DLBCL [123] and ibrutinib-resistant MCL [124].